UBS Group Forecasts Strong Price Appreciation for Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise (NASDAQ:AXON) had its price target lifted by analysts at UBS Group from $440.00 to $600.00 in a report released on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s target price indicates a potential upside of 5.08% from the stock’s previous close.

Several other equities research analysts have also weighed in on the company. Piper Sandler increased their target price on Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research report on Thursday. Citizens Jmp reaffirmed a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a research report on Thursday, June 25th. Weiss Ratings upgraded Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Barclays boosted their target price on Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $715.00 price objective on shares of Axon Enterprise in a research report on Thursday. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $730.92.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $571.01 on Thursday. The company has a 50 day moving average price of $513.80 and a 200 day moving average price of $474.59. The firm has a market capitalization of $46.02 billion, a price-to-earnings ratio of 236.93, a price-to-earnings-growth ratio of 10.66 and a beta of 1.39. Axon Enterprise has a one year low of $339.01 and a one year high of $878.62. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.93 and a current ratio of 2.15.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The business had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. During the same period last year, the business posted $2.12 EPS. The company’s revenue was up 35.3% on a year-over-year basis. Sell-side analysts anticipate that Axon Enterprise will post 1.63 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the sale, the chief executive officer owned 3,060,997 shares in the company, valued at $1,530,498,500. This represents a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $400.00, for a total transaction of $800,000.00. Following the completion of the sale, the insider owned 52,813 shares of the company’s stock, valued at $21,125,200. This trade represents a 3.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 58,989 shares of company stock valued at $30,527,983 in the last 90 days. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Brighton Jones LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at approximately $480,000. NewEdge Advisors LLC lifted its holdings in Axon Enterprise by 41.1% in the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after buying an additional 668 shares during the period. Empowered Funds LLC lifted its position in Axon Enterprise by 8.4% during the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after buying an additional 157 shares during the period. Woodline Partners LP lifted its holdings in shares of Axon Enterprise by 40.6% during the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Axon Enterprise in the 2nd quarter worth about $284,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Q2 growth and higher outlook: Axon reported second-quarter revenue of approximately $904 million, up 35% year over year and above analyst expectations. The company raised its 2026 revenue-growth forecast to 32%–34%, citing record bookings, international expansion and demand for its connected devices and software. Axon Beat Estimates and Raised Guidance, Shares Dropped
• Positive Sentiment: AI and Dedrone momentum: AI Era revenue, including Draft One automated police-report software, grew nearly 700% from a year earlier. Dedrone counter-drone revenue exceeded $100 million, supported by deployments at all 11 World Cup sites, strengthening Axon’s long-term growth narrative. Axon Stock Falls After AI, Drone Wins Fuel Q2 Earnings Beat
• Positive Sentiment: Analyst and retail support: UBS raised its price target to $600 while maintaining a Neutral rating, and retail traders showed interest in buying the post-earnings pullback. William Blair also reiterated a Buy rating, highlighting recurring-revenue growth, counter-drone demand and Axon’s expanding AI platform. UBS Raises Axon Price Target
• Neutral Sentiment: Valuation remains elevated: Axon’s rapid share-price recovery has increased scrutiny of its valuation. Some analysis considers the stock expensive on discounted cash flow and only fairly valued on sales multiples, potentially limiting further gains unless growth remains strong. Axon Stock Could Be Overvalued
• Negative Sentiment: Margins and cash flow pressured the initial reaction: Software gross margin declined to 71.3% from 75.6%, while a greater mix of professional services, memory costs and investments in new products reduced profitability. Free cash flow also turned negative, and quarterly EPS was reported as slightly below some consensus estimates, prompting an initial post-earnings selloff. Axon Posts Lower Quarterly Gross Margin

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.